title: Involvement of the kallikrein-kinin system in the salivary secretion elicited in rats by heat stress.
abstract: 1. During heat exposure, rats secrete large amounts of saliva. Salivation started when body temperature exceeded 39 degrees C and was reduced by kininogen deficiency or by HOE 140, a bradykinin antagonist. This secretory response was associated with a partial depletion of glandular kallikrein from the submaxillary glands. The depletion was abolished by simultaneous treatment of the animals with an alpha- and a beta-adrenergic antagonist. During heat exposure, plasma levels of kininogens were reduced. 2. Pilocarpine and substance P induced a similar flow of saliva in normal and kininogen-deficient rats and released low amounts of kallikrein from salivary glands. Phenylephrine and isoproterenol induced a larger flow of saliva in normal rats than in kininogen-deficient rats. Both agents released large amounts of kallikrein in saliva but isoproterenol was only active at large doses. 3. During heat exposure, the blood content of submaxillary glands in normal as well as in kininogen-deficient rats increased as a function of the ambient temperature. This increase was suppressed by atropine and NG-nitro-L-arginine, a NO-synthase inhibitor, but was not modified by HOE 140. Simultaneously, a swelling of the glands and of the surrounding soft tissues occurred in normal but not in kininogen-deficient rats. Kallikrein was present in the edema fluid. 4. The kallikrein-kinin system would thus participate in heat-induced salivary secretion and kinins may be a factor responsible for electrolyte and water exchanges in the glands.
authors.affiliation: Department of Human Physiology, Faculty of Medicine, University of Liège, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Damas
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006358:Hot Temperature / Q000009:adverse effects*; D016234:Kallikrein-Kinin System / Q000502:physiology*; D007610:Kallikreins / Q000378:metabolism; D007704:Kininogens / Q000172:deficiency; D008297:Male; D019335:Nitroarginine; D010862:Pilocarpine / Q000494:pharmacology; D051381:Rats; D011914:Rats, Inbred BN; D017208:Rats, Wistar; D012463:Saliva / Q000378:metabolism*; D013312:Stress, Physiological / Q000378:metabolism*; D013363:Submandibular Gland / Q000187:drug effects; D013373:Substance P / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D007704:Kininogens; D010862:Pilocarpine; D019335:Nitroarginine; D013373:Substance P; D001285:Atropine; C065679:icatibant; D001120:Arginine; D007610:Kallikreins; D001920:Bradykinin